Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage

Overview

1. To evaluate the effectiveness of Huperzine A injection in the treatment of brain injury in patients with hypertensive cerebral hemorrhage; 2. To evaluate the safety of Huperzine A injection in the treatment of brain injury in patients with hypertensive cerebral hemorrhage。

Full Title of Study: “A Randomized, Controlled, Single-center Clinical Study of Huperzine A in the Treatment of Brain Injury in Patients With Hypertensive Cerebral Hemorrhage”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 28, 2021

Detailed Description

A randomized, controlled, single-center, exploratory clinical research method was used. In the treatment plan, the experimental group used basic treatment + Huperzine A, and the control group only used basic treatment, with a total of 20 cases. To evaluate the effectiveness and safety of Huperzine A injection in the treatment of brain injury in patients with hypertensive cerebral hemorrhage.

Interventions

  • Drug: Huperzine A for Injection
    • Give the patient one intramuscular injection (0.2mg) of Huperzine A of injection once a day for 14 days

Arms, Groups and Cohorts

  • Experimental: Experimental:Huperzine A for Injection+Basic treatment
    • Huperzine A for Injection: Dissolve each bottle with 2ml sterile water for injection and inject into muscle, the course of treatment is 14 days; Basic treatment:Control blood pressure; prevent continued bleeding; prevent and treat gastrointestinal bleeding; decide whether to perform dehydration treatment according to the condition to reduce cerebral edema; prevent infection, prevent various complications, etc.; routine rehabilitation training.
  • No Intervention: Control:Basic treatment
    • Basic treatment:Control blood pressure; prevent continued bleeding; prevent and treat gastrointestinal bleeding; decide whether to perform dehydration treatment according to the condition to reduce cerebral edema; prevent infection, prevent various complications, etc.; routine rehabilitation training.

Clinical Trial Outcome Measures

Primary Measures

  • Extension of Glasgow Outcome Scale(GOSE) Scores at 90 days of treatment
    • Time Frame: At the 90-day
    • At the 90-day follow-up of patients, the extended Glasgow Outcome Scale (GOSE) was used to assess and judge the difference in consciousness after stroke between the two groups. The scores of minimum values is 1, the maximum values is 8, whether higher scores mean a better outcome.

Secondary Measures

  • Extension of Glasgow Outcome Scale(GOSE) Scores at 30 days of treatment
    • Time Frame: At the 30-day
    • At the 30-day follow-up of patients, the extended Glasgow Outcome Scale (GOSE) was used to assess and judge the difference in consciousness after stroke between the two groups. The scores of minimum values is 1, the maximum values is 8, whether higher scores mean a better outcome.
  • Scores of Modified Rankin Scale(mRS) at 14 days of treatment
    • Time Frame: At the 14-day
    • At 14 days of treatment, the two groups of patients were scored with scores of Modified Rankin Scale(mRS). The mRS score of the two groups were compared whether there were statistical differences. The scores of minimum values is 0, the maximum values is 5, whether higher scores mean a worse outcome.
  • Scores of Modified Rankin Scale(mRS) at 30 days of treatment
    • Time Frame: At the 30-day
    • At 30 days of treatment, the two groups of patients were scored with scores of Modified Rankin Scale(mRS). The mRS score of the two groups were compared whether there were statistical differences.The scores of minimum values is 0, the maximum values is 5, whether higher scores mean a worse outcome.
  • Scores of Modified Rankin Scale(mRS) at 90 days of treatment
    • Time Frame: At the 90-day
    • At 90 days of treatment, the two groups of patients were scored with scores of Modified Rankin Scale(mRS). The mRS score of the two groups were compared whether there were statistical differences.The scores of minimum values is 0, the maximum values is 5, whether higher scores mean a worse outcome.
  • Scores of National Institute of Health stroke scale(NIHSS) at 14 days of treatment
    • Time Frame: At the 14-day
    • At 14 days of treatment, the two groups of patients were scored with scores of National Institute of Health stroke scale(NIHSS). The NIHSS score of the two groups were compared whether there were statistical differences. The scores of minimum values is 0, the maximum values is 42, whether higher scores mean a worse outcome.
  • Scores of National Institute of Health stroke scale(NIHSS) at 30 days of treatment
    • Time Frame: At the 30-day
    • At 30 days of treatment, the two groups of patients were scored with scores of National Institute of Health stroke scale(NIHSS). The NIHSS score of the two groups were compared whether there were statistical differences. The scores of minimum values is 0, the maximum values is 42, whether higher scores mean a worse outcome.
  • Scores of National Institute of Health stroke scale(NIHSS) at 90 days of treatment
    • Time Frame: At the 90-day
    • At 90 days of treatment, the two groups of patients were scored with scores of National Institute of Health stroke scale(NIHSS). The NIHSS score of the two groups were compared whether there were statistical differences. The scores of minimum values is 0, the maximum values is 42, whether higher scores mean a worse outcome.
  • Scores of the Barthelindex of ADL at 14 days of treatment
    • Time Frame: At the 14-day
    • At 14 days of treatment, the two groups of patients were scored with scores of Barthelindex of ADL. The Barthelindex of ADL scores of the two groups were compared whether there were statistical differences. The scores of minimum values is 0, the maximum values is 100, whether higher scores mean a better outcome.
  • Scores of the Barthelindex of ADL at 30 days of treatment
    • Time Frame: At the 30-day
    • At 30 days of treatment, the two groups of patients were scored with scores of Barthelindex of ADL. The Barthelindex of ADL scores of the two groups were compared whether there were statistical differences. The scores of minimum values is 0, the maximum values is 100, whether higher scores mean a better outcome.
  • Scores of the Barthelindex of ADL at 90 days of treatment
    • Time Frame: At the 90-day
    • At 90 days of treatment, the two groups of patients were scored with scores of Barthelindex of ADL. The Barthelindex of ADL scores of the two groups were compared whether there were statistical differences. The scores of minimum values is 0, the maximum values is 100, whether higher scores mean a better outcome.
  • Complication rate
    • Time Frame: At the 90-day
    • After 90 days of treatment, compare whether the incidence of complications (including epilepsy, hydrocephalus, infarction, rebleeding, pneumonia, gastrointestinal hemorrhage) between the two groups is statistically different

Participating in This Clinical Trial

Inclusion Criteria

1. Aged from 18 to 75 years old(including 18 and 75 years old), males or females; 2. First onset, clinical diagnosis of hypertensive intracerebral hemorrhage, and CT confirmed that the amount of hemorrhage is between 15ml-50ml, the bleeding site is the basal ganglia, the bleeding has not penetrated into the lateral ventricle, and non-surgical patients; 3. Those with obvious neurological dysfunction after the onset, 5≤GCS≤15 or NIHSS≥6; 4. Admission within 72 hours after the onset of the disease, and no significant enlargement of the hematoma within 24 hours after admission (hematoma enlargement ≤ 5ml); 5. The patient/family knows and signs the informed consent form voluntarily. Exclusion Criteria:

1. Cerebral hemorrhage caused by cerebral aneurysm, brain tumor, brain trauma, cerebral parasitic disease, cerebrovascular malformation, abnormal blood vessel network at the base of the brain, cerebral arteritis, blood disease, metabolic disorder and other diseases confirmed by examination; 2. Patients with enlarged hematoma found within 24 hours after admission (the volume of enlarged hematoma> 5ml); 3. Patients with simple transient ischemic attack, lacunar infarction, subarachnoid hemorrhage and ischemic cerebral infarction; 4. Patients who use anticoagulant drugs for a long time; 5. Patients with platelet count <100,000, INR>1.4 at admission and abnormal blood coagulation function; 6. The measured value of homocysteine at admission is higher than 15μmol/L; 7. Patients who need surgical treatment (including ventricular drainage); 8. Patients with severe primary diseases such as cardiovascular, liver (ALT or AST>1.5 times the upper limit of normal), kidneys (BUN>1.5 times the upper limit of normal and Cr>upper limit of normal), endocrine system and hematopoietic system; 9. Those who are allergic to protein and test drugs; 10. People who are dependent on drugs or alcohol; 11. Intended pregnancy or women of childbearing age with positive pregnancy test and lactating women; 12. Participated in other clinical trials within the past 3 months; 13. Patients considered by the investigator to be inappropriate to participate in clinical trials.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Jiangsu Famous Medical Technology Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Fu Xudong, PhD, 13733167393, fxd1064@126.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.